Key result
Low-dose aspirin use significantly reduced the incidence of pre-eclampsia (13.2% vs 22.4%, HR 0.695) in high-risk pregnant women compared to no aspirin, without increasing the risk of postpartum hemorrhage.
Why the study?
The efficacy of low-dose aspirin in managing pre-eclampsia among high-risk pregnant women and its potential impact on postpartum hemorrhage remain contentious.
Does low-dose aspirin prevent pre-eclampsia in high-risk pregnant women?
Cohort (n=344)
No
Does low-dose aspirin prevent pre-eclampsia in high-risk pregnant women?
Hazard Ratio: 0.695 (95% CI 0.422–0.913)
Absolute Event Rate: 13.2% vs 22.4%
p-value: p=<0.001
Low-dose aspirin effectively reduces the incidence of pre-eclampsia and related complications in high-risk pregnancies without increasing the risk of postpartum hemorrhage.
Supports aspirin prophylaxis in high-risk pregnancies; leaves open confirmation by prospective RCTs before practice change.
Background Pre-eclampsia, characterized by hypertension and organ dysfunction during pregnancy, poses significant risks to both maternal and fetal health. Aspirin, known for its antiplatelet properties, has been extensively utilized to mitigate pregnancy-related complications. However, the efficacy of low-dose aspirin in managing pre-eclampsia among high-risk pregnant women and its potential impact on postpartum hemorrhage remain contentious topics. Methods A retrospective analysis was conducted on 344 pregnant women diagnosed with high-risk factors for pre-eclampsia. Among them, 152 received intervention with low-dose aspirin, while the rest did not receive it. The incidence of pre-eclampsia, as well as related complications and outcomes associated with bleeding, were compared and evaluated between the two groups. Results The study findings indicate a significant reduction in the incidence of pre-eclampsia among pregnant women receiving low-dose aspirin intervention, along with a significantly reduced risk of complications. Additionally, there was no significant statistical difference in postpartum hemorrhage between the two groups ( p > 0.05). The safety profile of aspirin usage was found to be favorable. Conclusion Low-dose aspirin demonstrates promising efficacy as an intervention strategy for high-risk preeclamptic women. It does not increase the risk of postpartum hemorrhage and reduces the occurrence of complications associated with preeclampsia. Therefore, low-dose aspirin presents a potential preventive measure against adverse outcomes associated with high-risk pregnancies related to preeclampsia. Further research is necessary to validate and elucidate the optimal dosage and timing of administration for maximal benefits.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2024) conducted a cohort in Pre-eclampsia (n=344). Low-dose aspirin vs. No aspirin was evaluated on Incidence of pre-eclampsia (HR 0.695, 95% CI 0.422-0.913, p=<0.001). Low-dose aspirin use significantly reduced the incidence of pre-eclampsia (13.2% vs 22.4%, HR 0.695) in high-risk pregnant women compared to no aspirin, without increasing the risk of postpartum hemorrhage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: